Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

A group of more than 100 Democratic lawmakers sent a letter to President Donald Trump on Friday warning about the potential ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...

George House Trust, which helps people across Greater Manchester and Liverpool, was one of 10 winners of the 2025 GSK Impact ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...

GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophylaxis (PrEP) available in ...